Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors-Reference-Cited by-同舟云学术

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors

Published:2013-11 Issue:4 Volume:5 Page:1047-1059
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Waibel Michaela,Solomon Vanessa S.,Knight Deborah A.,Ralli Rachael A.,Kim Sang-Kyu,Banks Kellie-Marie,Vidacs Eva,Virely Clemence,Sia Keith C.S.,Bracken Lauryn S.,Collins-Underwood Racquel,Drenberg Christina,Ramsey Laura B.,Meyer Sara C.,Takiguchi Megumi,Dickins Ross A.,Levine Ross,Ghysdael Jacques,Dawson Mark A.,Lock Richard B.,Mullighan Charles G.,Johnstone Ricky W.

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference42 articles.

1. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms;Atallah;Expert Rev. Anticancer Ther.,2009

2. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders;Baxter;Lancet,2005

3. TEL-JAK2 transgenic mice develop T-cell leukemia;Carron;Blood,2000

4. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics;Cragg;Nat. Rev. Cancer,2009

5. Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB;Dai;Exp. Hematol.,2005

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in JAK2 inhibition for the treatment of myelofibrosis;Expert Opinion on Pharmacotherapy;2024-06-12

2. A novel application of XPO1 inhibition for the treatment of myelofibrosis;Blood Neoplasia;2024-06

3. Tyrosine phosphorylation of CARM1 promotes its enzymatic activity and alters its target specificity;Nature Communications;2024-04-22

4. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements;Cancers;2024-01-25

5. New era for myelofibrosis treatment with novel agents beyond Janus kinase‐inhibitor monotherapy: Focus on clinical development of BCL‐X_L/BCL‐2 inhibition with navitoclax;Cancer;2023-08-16